AMEX · IBO
Healthcare · Biotechnology
$3.80
Down-$0.07 (-1.81%)
Updated Nov 1, 2026, 2:31 AM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · IBO
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
IBO closed at $3.80 after 20 trading sessions, down 21.49% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $3.52 | $4.10 | $3.52 | $3.80 | 15.29K |
| Oct 29, 2026 | $4.25 | $4.25 | $3.71 | $3.87 | 23.86K |
| Oct 28, 2026 | $3.40 | $4.38 | $3.40 | $3.9899 | 39.89K |
| Oct 27, 2026 | $3.78 | $4.11 | $3.55 | $3.55 | 12.27K |
| Oct 26, 2026 | $3.74 | $3.88 | $3.10 | $3.73 | 12.61K |
| Oct 23, 2026 | $3.69 | $4.0198 | $3.54 | $3.60 | 11.83K |
| Oct 22, 2026 | $3.82 | $4.23 | $3.60 | $3.80 | 21.55K |
| Oct 21, 2026 | $3.60 | $4.32 | $3.60 | $4.02 | 27.68K |
| Oct 20, 2026 | $2.78 | $3.42 | $2.6738 | $3.2675 | 12.34K |
| Oct 19, 2026 | $2.66 | $3.75 | $2.66 | $3.06 | 47.95K |
| Oct 16, 2026 | $3.21 | $3.21 | $2.43 | $2.68 | 10.21K |
| Oct 15, 2026 | $3.17 | $4.08 | $2.62 | $3.1584 | 29.04K |
| Oct 14, 2026 | $3.59 | $3.85 | $3.2501 | $3.4034 | 3.97K |
| Oct 13, 2026 | $4.11 | $4.11 | $3.84 | $3.98 | 9.48K |
| Oct 12, 2026 | $4.25 | $4.46 | $4.00 | $4.03 | 7.39K |
| Oct 9, 2026 | $4.13 | $4.39 | $4.13 | $4.25 | 4.03K |
| Oct 8, 2026 | $4.32 | $4.41 | $4.06 | $4.11 | 17.56K |
| Oct 7, 2026 | $4.57 | $4.59 | $4.36 | $4.48 | 10.74K |
| Oct 6, 2026 | $5.00 | $5.05 | $4.43 | $4.68 | 21.17K |
| Oct 5, 2026 | $5.16 | $5.42 | $4.84 | $4.84 | 17.34K |
The latest Smart Investors Daily articles mentioning IBO.
Company
Market Activity
Research & News
IBO research
Company profile and research snapshot.
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Oct 26, 2026
Gainers SciSparc (NASDAQ:SPRC) shares moved upwards by 39.4% to $1.52 during Monday's pre-market session. Xencor (NASDAQ:XNCR) stock moved upwards by 29.46% to $32.6. The company's market cap stands at $1.9
Yahoo · Sep 16, 2026
ROCHESTER, N.Y., Sept. 16, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) (“DSS” or the “Company”) today announced that Zoar Limited (“Zoar” or “PubCo”) has filed a Registration Statement on Form F-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) in connection with the previously announced proposed business combination (the “Business Combination”) involving Impact Biomedical Inc. (NYSE American: IBO) (“Impact”), Zoar and certain related parties.
Yahoo · Sep 16, 2026
HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (NYSE: IBO) (the “Company” or “Impact”) announced that a Form F-4 registration statement (the “Registration Statement”) was filed with the U.S. Securities and Exchange Commission (the “SEC”) on Thursday, September 10, 2026, by Zoar Limited (“PubCo”) in connection with the previously announced business combination (the “Business Combination”) with, among others, PubCo and Zoar Labs Limited (f/k/a Dr. Ashley’s Bio Labs Limited) (“Z
Yahoo · Sep 15, 2026
HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- This corrected press release is being issued to correct the merger exchange ratio that was incorrectly stated in the press release of Impact Biomedical Inc. (the “Company” or “Impact”) dated September 11, 2026. The original press release incorrectly stated that Impact stockholders would receive one (1) share of Zoar Limited for every four (4) shares of Impact Common Stock (defined below). The correct exchange ratio, as set forth in the Merger and Share
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IBO.
